Trulieve Cannabis’ (TRLV) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Trulieve Cannabis (NYSE:TRLV) in a research report sent to investors on Friday,Benzinga reports. They currently have a $15.00 target price on the stock.

A number of other analysts also recently commented on TRLV. Weiss Ratings restated a “sell (d-)” rating on shares of Trulieve Cannabis in a report on Friday, September 11th. Wall Street Zen lowered Trulieve Cannabis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $15.00.

Trulieve Cannabis Stock Performance

Shares of TRLV stock opened at $10.40 on Friday. Trulieve Cannabis has a one year low of $4.62 and a one year high of $13.28. The company has a quick ratio of 3.98, a current ratio of 5.94 and a debt-to-equity ratio of 0.45. The stock’s 50 day moving average is $11.17. The firm has a market capitalization of $2.00 billion and a price-to-earnings ratio of 94.52.

Trulieve Cannabis (NYSE:TRLV) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.05. The company had revenue of $271.00 million for the quarter, compared to the consensus estimate of $268.82 million. Trulieve Cannabis had a negative net margin of 41.55% and a negative return on equity of 4.24%. As a group, equities analysts forecast that Trulieve Cannabis will post 0.31 EPS for the current fiscal year.

Institutional Trading of Trulieve Cannabis

A number of institutional investors have recently modified their holdings of the company. Prime Capital Investment Advisors LLC acquired a new stake in Trulieve Cannabis during the 3rd quarter worth approximately $770,000. Marion Wealth Management purchased a new position in Trulieve Cannabis in the third quarter valued at approximately $109,000. Finally, PFS Partners LLC acquired a new position in Trulieve Cannabis during the third quarter valued at approximately $33,000.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes and sells medical and adult-use cannabis products. Its offerings include flower, pre-rolls, concentrates, vaporizers, edibles, tinctures, capsules and topical products, sold through retail dispensaries and other approved channels under brands such as Trulieve, Cultivar Collection, Muse, Roll One and Alchemy.

Founded in 2015, Trulieve initially built its business around Florida’s medical cannabis market and later expanded into additional U.S.